STOK stoketherapeutics.com: Enterprise Value to EBITDA Ratio
The current EV/EBITDA value for Stoke Therapeutics (STOK) in the GURU.Markets chart data is recorded at 0.00, reflecting the metric's latest value. High bioengineering costs and patent protection create a formidable barrier to entry for competitors. A liquid reserve ensures financial stability, and the business remains independent of market cycles. Tremendous potential lies in the development of therapies for rare epilepsies.
STOK (stoketherapeutics.com): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Stoke Therapeutics|STOK - Long-Term Liabilities to Capital|Short-Term Debt to Equity Stoke Therapeutics, Inc.|STOK - Aggregate Debt Obligations|Debts to Book Capitalization Stoke Corp|STOK - Company Long-Term Debts|Company Short-Term Debt Stoke Therapeutics|Quick Ratio stoketherapeutics.com
- net income and valuation multiples indicators:
STOK - Company Net Income|Future Profit Stoke Therapeutics|STOK - P/E Multiple|Projected Price to Earnings Stoke Therapeutics|STOK - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Stoke Corp|STOK - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Stoke Therapeutics|STOK - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months stoketherapeutics.com|STOK - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Stoke Therapeutics
Summary company analysis:Stoke STOK
This multiple determines the business value relative to its operating profit, allowing for an assessment of the leveraged structure's resilience to market shocks. By analyzing the Enterprise Value to EBITDA trend, an investor can see the ratio of total capital to yield, which is critical for Stoke Therapeutics (STOK) in securing long-term funding for high-tech RNA therapy research and retaining leading geneticists.
Competitors of Stoke Therapeutics
EV/EBITDA Multiple TEM (tempus.com)|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRSP: Enterprise Value to Operating Income Before Depreciation Ratio|WGS (Sema4) - EV/EBITDA Multiple|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|BLFS - EV/EBITDA Multiple|Wave Life Sciences (WVE) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MAZE (mazetx.com)|SION (Sionna Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Prime Medicine Inc PRME|Enterprise Value to EBITDA Ratio TSHA (Taysha)|EV/EBITDA Multiple uniQure Pharma (QURE)|MeiraGTx Holdings plc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio RGNX (regenxbio.com)|Solid Biosciences - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ocugen Inc OCGN|PACB: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Benitec Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Design Therapeutics|rocketpharma.com (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Korro Bio - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio EDIT (Editas Corp)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA ProQR Therapeutics N.V.|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Sangamo Therapeutics Inc. (SGMO) - EV/EBITDA Multiple|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|RNAZ: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Company Value to EBITDA Applied DNA Sciences Inc APDN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|EV/EBITDA Multiple immunoprecise.com (IPA)|EV/EBITDA Multiple OMGA (Omega Therapeutics)|singulargenomics.com (OMIC) - Company Value to EBITDA|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TCON: Enterprise Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
